Bed Bath & Beyond (BBBY) numbers were cut at J.P. Morgan. Twelve-month price target is now $75. Estimates were also reduced, given margin pressure, J.P. Morgan said. Neutral rating.

Bed Bath & Beyond 12-month price target was cut at Barclays to $80. Lower-than-expected fourth-quarter numbers and ongoing deterioation of gross margins, Barclays said.

Charles River Laboratories (CRL) 12-month price target was increased to $73 at Jefferies. Earnings estimates were also increased. Outsourced R&D spending is expected to grow with biotech funding contributing, Jefferies said. Buy rating.

Covance (CVD) 12-month price target was raised to $117 at Jefferies. Driven by exposure to biotech and early development, Jefferies said. Buy rating.

Delphi (DLPH) 12-month price target was raised at Barclays to $82. Driven by exposure to secular growth and margin moats, Barclays said.

MSC Industrial Direct (MSM) 12-month price target was increased at UBS to $93. Beat on margins despite weather and improving operating improvement, UBS said. Neutral rating.

Constellation Brands (STZ) numbers were boosted at Societe Generale. Twelve-month price target is now $77. Estimates were also increased, given higher growth in the beer business, Societe Generale said. Sell rating.

Follow TheStreet on Twitter and become a fan on Facebook

This article was written by a staff member of TheStreet.

If you liked this article you might like

Coolest Apple iOS 11 Features That You Might Have Missed

Apple iPhone 8 and iOS 11's Positive Reviews Bode Well for the iPhone X

Best Buy CEO -- We, Together With Amazon, Will 'Kill' the Competition

A Sprint/T-Mobile Deal Still Faces Big Hurdles, Especially for Sprint

How to Make a Deal Like Billionaire Investor Warren Buffett